Aliases & Classifications for Withdrawal Disorder

MalaCards integrated aliases for Withdrawal Disorder:

Name: Withdrawal Disorder 12 14
Substance Withdrawal Syndrome 69
Withdrawal Syndrome 51

Classifications:



External Ids:

Disease Ontology 12 DOID:0060001
UMLS 69 C0038587

Summaries for Withdrawal Disorder

Disease Ontology : 12 A substance-related disorder that occurs upon the abrupt discontinuation/separation or a decrease in dosage of the intake of medications, recreational drugs, and alcohol.

MalaCards based summary : Withdrawal Disorder, also known as substance withdrawal syndrome, is related to barbiturate dependence and neonatal abstinence syndrome, and has symptoms including opiate withdrawal symptoms, withdrawal symptoms and drug withdrawal symptoms. An important gene associated with Withdrawal Disorder is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Peptide ligand-binding receptors and Pathways in cancer. Related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Withdrawal Disorder

Diseases related to Withdrawal Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Related Disease Score Top Affiliating Genes
1 barbiturate dependence 11.2
2 neonatal abstinence syndrome 10.8
3 nodular prostate 10.5 AR KLK3
4 prostatic adenoma 10.5 AR KLK3
5 prostatic acinar adenocarcinoma 10.5 AR KLK3
6 cyclic vomiting syndrome 10.4 CNR1 OPRM1
7 chronic pain 10.4 CNR1 OPRM1
8 prostatic hyperplasia, benign 10.4 AR KLK3
9 androgenic alopecia 10.4 AR KLK3
10 opioid abuse 10.4 OPRM1 PDYN
11 morphine dependence 10.3 FOS OPRM1
12 motion sickness 10.3 FOS HTR7
13 heroin dependence 10.3 OPRM1 PDYN
14 prostatic hypertrophy 10.2 AR KLK3
15 atypical depressive disorder 10.1 CRH HTR7
16 drug-induced mental disorder 10.1 CNR1 FOS HTR7
17 drug psychosis 10.1 CNR1 FOS HTR7
18 prostate adenoid cystic carcinoma 10.1 KLK3 POMC
19 tuberculous epididymitis 10.1 KLK3 POMC
20 suprasellar meningioma 10.1 KLK3 POMC
21 migraine with or without aura 1 10.1 CNR1 FOS HTR7
22 retrograde amnesia 10.0 PDYN POMC
23 separation anxiety disorder 10.0 HTR7 TSPO
24 cystitis cystica 10.0 AR KLK3
25 cutaneous solitary mastocytoma 9.9 PDYN POMC
26 anxiety 9.9 CNR1 CRH TSPO
27 sex differentiation disease 9.9 AR POMC
28 gynecomastia 9.9 AR KLK3 POMC
29 substance dependence 9.8 CNR1 OPRM1 POMC
30 opiate dependence 9.8 OPRM1 PDYN POMC
31 cocaine dependence 9.8 OPRM1 PDYN POMC
32 hypothalamic disease 9.8 CRH POMC
33 acth deficiency, isolated 9.8 CRH POMC
34 pituitary carcinoma 9.8 CRH POMC
35 nelson syndrome 9.8 CRH POMC
36 sheehan syndrome 9.8 CRH POMC
37 hypoadrenalism 9.8 CRH POMC
38 acth-secreting pituitary adenoma 9.8 CRH POMC
39 fasting hypoglycemia 9.7 CRH POMC
40 adrenal cortical hypofunction 9.7 CRH POMC
41 persistent fetal circulation syndrome 9.7 CRH POMC
42 adrenal cortex disease 9.6 CRH POMC
43 urinary system disease 9.6 CRH KLK3 POMC
44 gonadal disease 9.6 AR CRH POMC
45 adrenal gland disease 9.6 CRH POMC
46 panic disorder 9.6 CRH POMC TSPO
47 ectopic cushing syndrome 9.6 CRH POMC
48 mental depression 9.5 CRH HTR7 POMC
49 premenstrual tension 9.5 CRH POMC
50 pheochromocytoma 9.5 CRH FOS POMC

Graphical network of the top 20 diseases related to Withdrawal Disorder:



Diseases related to Withdrawal Disorder

Symptoms & Phenotypes for Withdrawal Disorder

UMLS symptoms related to Withdrawal Disorder:


opiate withdrawal symptoms, withdrawal symptoms, drug withdrawal symptoms, seizures

MGI Mouse Phenotypes related to Withdrawal Disorder:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.16 AR CNR1 CRH FOS HTR7 JAG1
2 homeostasis/metabolism MP:0005376 10.06 CNR1 CRH FOS HTR7 JAG1 NPL
3 cellular MP:0005384 10.03 FOS JAG1 OPRM1 POMC TSPO AR
4 growth/size/body region MP:0005378 10.02 AR CNR1 CRH FOS JAG1 OPRM1
5 adipose tissue MP:0005375 9.95 AR CNR1 CRH OPRM1 PDYN POMC
6 endocrine/exocrine gland MP:0005379 9.95 AR CRH FOS JAG1 OPRM1 POMC
7 integument MP:0010771 9.91 AR CNR1 CRH FOS HTR7 JAG1
8 nervous system MP:0003631 9.81 AR CNR1 CRH FOS HTR7 JAG1
9 no phenotypic analysis MP:0003012 9.43 CNR1 CRH JAG1 OPRM1 PDYN POMC
10 normal MP:0002873 9.17 JAG1 OPRM1 TSPO AR CNR1 CRH

Drugs & Therapeutics for Withdrawal Disorder

Genetic Tests for Withdrawal Disorder

Anatomical Context for Withdrawal Disorder

Publications for Withdrawal Disorder

Articles related to Withdrawal Disorder:

(show top 50) (show all 52)
# Title Authors Year
1
The Impact of Saffron on Symptoms of Withdrawal Syndrome in Patients Undergoing Maintenance Treatment for Opioid Addiction in Sabzevar Parish in 2017. ( 29359178 )
2017
2
Addison's Disease and Possible Cannabis Withdrawal Syndrome Presenting as an Eating Disorder in a Thirty-Year-Old Female. ( 28348901 )
2017
3
Transdermal Scopolamine Withdrawal Syndrome Case Report in the Pediatric Cerebral Palsy Population. ( 28081025 )
2017
4
Carisoprodol withdrawal syndrome resembling neuroleptic malignant syndrome: Diagnostic dilemma. ( 27625493 )
2016
5
Efficacy of acamprosate for the treatment of alcohol dependence long after recovery from withdrawal syndrome: a randomized, double-blind, placebo-controlled study conducted in Japan (Sunrise Study). ( 25742205 )
2015
6
Sodium oxybate in the treatment of alcohol dependence: from the alcohol withdrawal syndrome to the alcohol relapse prevention. ( 24283802 )
2014
7
Evaluation of prostate-specific antigen response following cessation of abiraterone acetate: is there evidence for a withdrawal syndrome? ( 24210911 )
2014
8
Sodium oxybate: a review of its use in alcohol withdrawal syndrome and in the maintenance of abstinence in alcohol dependence. ( 24307430 )
2014
9
Dopamine agonist withdrawal syndrome in a patient with restless legs syndrome without impulse control disorder or drug abuse. ( 25362251 )
2014
10
Opioid withdrawal syndrome after treatment with low-dose extended-release oxycodone and naloxone in a gastric cancer patient with portal vein thrombosis. ( 23680581 )
2013
11
Dopamine agonist withdrawal syndrome in a patient with restless legs syndrome. ( 22749683 )
2013
12
Influence of DRD2 and ANKK1 polymorphisms on the manifestation of withdrawal syndrome symptoms in alcohol addiction. ( 23238469 )
2012
13
Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft. ( 19790238 )
2010
14
Intra-cornu ammonis 1 administration of the human immunodeficiency virus-1 protein trans-activator of transcription exacerbates the ethanol withdrawal syndrome in rodents and activates N-methyl-D-aspartate glutamate receptors to produce persisting spatial learning deficits. ( 19619615 )
2009
15
[Estramustine phosphate withdrawal syndrome in relapsed prostate cancer: two case reports]. ( 18634439 )
2008
16
Carisoprodol withdrawal syndrome misdiagnosed as a psychotic disorder. ( 18633744 )
2008
17
Genetic dissociation of two behaviors associated with nicotine addiction: beta-2 containing nicotinic receptors are involved in nicotine reinforcement but not in withdrawal syndrome. ( 16752141 )
2006
18
Withdrawal syndrome in a drug addict caused diagnostic delay of spontaneous bilateral carotid artery dissection. ( 15632548 )
2005
19
Impact of alcohol intoxication and withdrawal syndrome on social phobia and panic disorder in alcoholic inpatients. ( 15361983 )
2004
20
Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? ( 14668077 )
2003
21
Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. ( 12517791 )
2003
22
Behavioral effects of potentiated antibodies to morphine and mu-opioid receptors during withdrawal syndrome. ( 12949640 )
2003
23
Role of central histaminergic system in lorazepam withdrawal syndrome in rats. ( 11526976 )
2001
24
Neonatal paroxetine withdrawal syndrome or actually serotonin syndrome? ( 11561552 )
2001
25
Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance. ( 11085345 )
2000
26
GH dependence and GH withdrawal syndrome in GH treatment of short normal children: evidence from growth and cardiac output. ( 9578507 )
1998
27
[Antiandrogen withdrawal syndrome]. ( 9750522 )
1998
28
Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression. ( 9634122 )
1998
29
Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer. ( 9854191 )
1998
30
Incidence and characteristics of antiandrogen withdrawal syndrome in prostate cancer after treatment with chlormadinone acetate. ( 9743699 )
1998
31
The antiandrogen withdrawal syndrome. ( 9144890 )
1997
32
[An equivalent of anti-androgen withdrawal syndrome: decrease of prostate specific antigen and clinical response to estramustine phosphate withdrawal]. ( 9180872 )
1997
33
[The antiandrogen withdrawal syndrome: decrease in prostate specific antigen serum levels after withdrawal of antiandrogens]. ( 9471771 )
1997
34
The antiandrogen withdrawal syndrome in relapsed prostate cancer. ( 9074903 )
1997
35
Antiandrogen withdrawal syndrome with nilutamide. ( 9111642 )
1997
36
[Antiandrogen withdrawal syndrome in the hormonal treatment of metastatic prostatic cancer in hormonal escape]. ( 8624534 )
1996
37
Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. ( 8827083 )
1996
38
Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer. ( 7545251 )
1995
39
Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate. ( 7536369 )
1995
40
The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. ( 8620419 )
1995
41
Tolerance, drug dependence and withdrawal syndrome in antiepileptic drugs. ( 8655043 )
1995
42
Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. ( 7538601 )
1995
43
Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. ( 7510915 )
1994
44
Involvement of D2 dopamine receptors in the nucleus accumbens in the opiate withdrawal syndrome. ( 7915401 )
1994
45
Double-blind study of alprazolam, diazepam, clonidine, and placebo in the alcohol withdrawal syndrome: preliminary findings. ( 7978098 )
1994
46
Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. ( 7679759 )
1993
47
Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. ( 7687666 )
1993
48
alpha N-acetyl human beta-endorphin-(1-31) alleviates the morphine withdrawal syndrome in rodents: a comparative study with clonidine. ( 1608292 )
1992
49
Hyperphosphatemia as a detectable laboratory manifestation of glucocorticoid withdrawal syndrome. ( 3508717 )
1986
50
Suppression by progabide of ethanol withdrawal syndrome in rats. ( 2985405 )
1985

Variations for Withdrawal Disorder

Expression for Withdrawal Disorder

Search GEO for disease gene expression data for Withdrawal Disorder.

Pathways for Withdrawal Disorder

GO Terms for Withdrawal Disorder

Biological processes related to Withdrawal Disorder according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.75 CNR1 FOS OPRM1
2 G-protein coupled receptor signaling pathway GO:0007186 9.73 CNR1 CRH HTR7 OPRM1 PDYN POMC
3 aging GO:0007568 9.72 CNR1 FOS TSPO
4 response to ethanol GO:0045471 9.63 CNR1 CRH OPRM1
5 negative regulation of blood pressure GO:0045776 9.57 CNR1 CRH
6 response to morphine GO:0043278 9.56 CNR1 OPRM1
7 response to immobilization stress GO:0035902 9.54 CRH FOS
8 response to pain GO:0048265 9.52 CRH TSPO
9 adrenal gland development GO:0030325 9.51 CRH TSPO
10 neuropeptide signaling pathway GO:0007218 9.5 OPRM1 PDYN POMC
11 regulation of NMDA receptor activity GO:2000310 9.48 CRH OPRM1
12 chemical synaptic transmission GO:0007268 9.46 CRH HTR7 OPRM1 PDYN
13 response to corticosterone GO:0051412 9.43 CRH FOS
14 sensory perception GO:0007600 9.4 OPRM1 PDYN
15 regulation of synaptic transmission, GABAergic GO:0032228 9.37 CNR1 NISCH
16 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.13 CNR1 HTR7 OPRM1
17 response to cocaine GO:0042220 8.8 CNR1 CRH OPRM1
18 signal transduction GO:0007165 10.04 AR CNR1 CRH HTR7 OPRM1 POMC

Molecular functions related to Withdrawal Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 androgen binding GO:0005497 8.96 AR TSPO
2 neuropeptide hormone activity GO:0005184 8.8 CRH PDYN POMC

Sources for Withdrawal Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....